. LVAD thrombosis is a devastating complication, as it usually results either in the need for urgent transplantation or LVAD replacement or in death (3, 5, 6) . A number of causes of LVAD thrombosis have been postulated, including underanticoagulation, inadequate antiplatelet therapy, platelet activation by device materials or shear stress, decreased flow rates with bearing heating and denaturation of coagulation proteins, abnormal angulation of the inflow cannula, new materials in the device, infection, overestimation of the level of anticoagulation using the activated partial thromboplastin time, and right ventricular failure (7) (8) (9) . It is likely that many of these factors contribute to LVAD thrombosis, and in this issue of JACC: Heart Failure, yet another cause of LVAD thrombosis is described-erythropoiesis stimulating agents (ESAs). ESAs include several forms of erythropoietin-a glycoprotein produced in the kidney that acts on hematopoietic precursor cells to increase the production of red blood cells. The most commonly used human recombinant erythropoietins (epoetin alfa, epoetin beta, and darbepoetin alpha) differ primarily in glycosylation patterns and duration of action, but have similar effects on increasing red cell production and similar safety profiles (10).
In this issue of JACC: Heart Failure, Nassif et al. (11) report a retrospective, single-center study of 212
HeartMate II LVAD recipients, demonstrating an increased risk of suspected LVAD thrombosis in those who received ESAs. ESAs were used in this study, as anemia is common in LVAD recipients, often in association with low erythropoietin levels (12) . An increase in hemoglobin in LVAD recipients who are to be bridged to transplant is likely to reduce the need for blood products and, thus, reduce sensitization to human leukocyte antigens (HLA) (13) . This is important, as anti-HLA antigens may prolong the time to an adequate donor match in patients listed for transplantation (14) .
In this study, suspected LVAD thrombosis was defined as: 1) direct observation of obstructive thrombus in the pump or conduit; or 2) severe hemolysis, as defined by either a lactate dehydrogenase (LDH) level >4 times the upper limit of normal or a plasma-free hemoglobin >40 mg/dl, and symptoms of decompensated heart failure (HF). Using an inverse probability-weighted analysis, the authors found that the risk of suspected LVAD thrombosis in the cohort that received ESAs was nearly 2 times higher than in was an increased rate of thromboembolic events
Lindenfeld and Keebler shown that thrombopoiesis related to iron deficiency is associated with an excess mortality in dialysis patients (29, 30) .
In the study by Nassif et al. (11), baseline iron saturations were similar in the 2 groups, and previous clinical trials have considered the level in this study to be iron deficient for patients in an inflammatory milieu such as HF (32) . We do not know if iron was routinely monitored and repleted in the study, and baseline, discharge, or follow-up platelet counts are not reported, so iron deficiency cannot be excluded as a potential cause. Iron deficiency has also been reported to be a cause of increased oxidative stress-another factor that might exacerbate thrombosis (28, 31) .
ESAs directly stimulate thrombopoiesis as well as erythropoiesis, and this effect may be another cause of thrombosis (16, 28, (33) (34) (35) . Thrombocytosis has been associated with poor outcomes in patients with acute coronary syndromes even in the absence of ESAs, and this association was thought to be due to increased thrombosis (36) . ESAs also may directly result in endothelial activation leading to thrombosis (34) .
There are a number of other direct but non- 
